Novartis turns down right to buy Israeli stem cell group – PharmaTimes
Globes |
Novartis turns down right to buy Israeli stem cell group
PharmaTimes Swiss drug giant Novartis has decided not buy Israel-headquartered stem cell specialist Gamida Cell. Under an August 2014 pact which saw initial investment of $35 million, Novartis agreed to pay Gamida shareholders a further $165 million if it … Novartis nixes another $600M buyout deal for Gamida Cell Novartis won't exercise option to buy Gamida Cell Elbit Imaging Announces Termination of Option to Purchase Gamida Cell Ltd. |
